<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590575</url>
  </required_header>
  <id_info>
    <org_study_id>SZ_G_023.14-II-4</org_study_id>
    <nct_id>NCT02590575</nct_id>
  </id_info>
  <brief_title>&quot;Low Flow&quot; CO2 Removal on RRT</brief_title>
  <acronym>Prismalung</acronym>
  <official_title>&quot;Low Flow&quot; CO2 Removal Via a Membrane Gas Exchange Device (Prismalung®) on a Renal Replacement Platform (Prismaflex®) in Hypercapnic, Ventilated Patients Requiring Renal Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of a membrane gas exchange device in&#xD;
      the venovenous circulation of a continuous renal replacement therapy for the purpose of CO2&#xD;
      elimination and pH compensation. Thus, the primary endpoint is the modification of the PaCO2&#xD;
      and/or the ventilator settings (tidal volume VT and plateau pressure Pplat).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol synopsis Study title &quot;Low flow&quot; CO2 removal via a membrane gas exchange device&#xD;
      (Prismalung®) on a renal replacement platform (Prismaflex®) in hypercapnic, ventilated&#xD;
      patients requiring renal replacement therapy Brief description Prismalung Study Indication&#xD;
      Hypercapnic, ventilated, and renal replacement therapy requiring patients Primary study goal&#xD;
      Changes in the arterial pCO2 value Secondary study goals Changes in the acid-base balance&#xD;
      Changes of tidal volumes/ventilation pressures Changes in hemodynamics Study design&#xD;
      Prospective intervention study (pilot study)&#xD;
&#xD;
      Study population Inclusion criteria:&#xD;
&#xD;
        1. Necessity of renal replacement therapy&#xD;
&#xD;
        2. Necessity of ventilation therapy with an expected duration &gt;24 hrs. in mild to moderate&#xD;
           ARDS according to the &quot;Berlin Definition&quot; (300≥PaO2/FiO2&gt;100mmHg, ventilated acc. to the&#xD;
           ARDS network strategy with VT 6 ml/kgKG (KG = Körpergewicht, body weight) and PEEP ≥ 5&#xD;
           cmH2O)Pneumonia, pulmonary vasculitis, COPD, or other pulmonary disorder&#xD;
&#xD;
        3. PaCO2 ≥ 55 mmHg with plateau ventilation pressure &gt; 25 cmH2O and pH &lt; 7.30&#xD;
&#xD;
        4. Written consent by patient or legal representative&#xD;
&#xD;
      Number of patients n = 20 Interventions 1. With ongoing continuous hemofiltration and&#xD;
      mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal&#xD;
      replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep&#xD;
      gas flows 2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching&#xD;
      the initial PaCO2value Study drug None Primary endpoint 1. Changes in the PaCO2 / acid-base&#xD;
      status (BGA) 2. Changes of the VT / plateau pressure in the ventilation (ventilation&#xD;
      settings) Secondary endpoints Changes in the systemic hemodynamics Vasopressor dosage BGA,&#xD;
      renal values, lactate PaCO2 before and after gas exchange device Lifetimes of the&#xD;
      extracorporeal circulation Complications Study site Intensive care units Medizinische Klinik&#xD;
      4, Uniklinikum Erlangen-Nürnberg Medizinische Klinik 4, Klinikum Nürnberg Süd Klinik für&#xD;
      Intensivmedizin Universitätsklinikum Hamburg Eppendorf Klinik für Anästhesiologie und&#xD;
      Intensivmedizin Universitätsklinikum Frankfurt a. M. Timeline Start in October 2015&#xD;
      Anticipated study duration: 6 months Financing Baxter Gambro Renal GmbH (Ltd)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the PaCO2, acid-base status (BGA)</measure>
    <time_frame>hours to 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of the VT / plateau pressure in the ventilation (ventilation settings)</measure>
    <time_frame>hours to 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in mean arterial pressure (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate (bpm)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in norepinephrin dose (mg/h)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum lactate concentration (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial pO2 and pCO2 (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial bicarbonate concentration (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Base Excess (mmol/l)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum creatinine (mg/dl)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCO2 before and after gas exchange device (mmHg)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lifetime of extracorporeal circuit in hours (Duration from start to end of RRT)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and kind of adverse events during study period deemed clinically significant by investigator (as documented by paper questionnaire)</measure>
    <time_frame>hours to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>CO2 removal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform</intervention_name>
    <description>With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows&#xD;
Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value</description>
    <arm_group_label>CO2 removal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Necessity of renal replacement therapy&#xD;
&#xD;
          2. Necessity of ventilation therapy with an expected duration &gt;24 hrs. in mild to&#xD;
             moderate ARDS according to the &quot;Berlin Definition&quot; (300≥PaO2/FiO2&gt;100mmHg, ventilated&#xD;
             acc. to the ARDS network strategy with VT 6 ml/kgKG (KG = Körpergewicht, body weight)&#xD;
             and PEEP ≥ 5 cmH2O) Pneumonia, pulmonary vasculitis, COPD, or other pulmonary disorder&#xD;
&#xD;
          3. PaCO2 ≥ 55 mmHg with plateau ventilation pressure &gt; 25 cmH2O and pH &lt; 7.30&#xD;
&#xD;
          4. Written consent by patient or legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. BMI &gt; 40 kg/m2&#xD;
&#xD;
          4. Decompensated heart failure or acute stroke&#xD;
&#xD;
          5. Severe ARDS (PaO2/FiO2 &lt; 100 mmHg)&#xD;
&#xD;
          6. Acute cranio-cerebral injury&#xD;
&#xD;
          7. Severe liver failure (Child-Pugh score &gt;7)&#xD;
&#xD;
          8. Heparin-induced thrombopenia (HIT II)&#xD;
&#xD;
          9. Contraindications to the performance of CVVH (continuous venovenous hemofiltration)&#xD;
&#xD;
         10. Contraindications to systemic anticoagulation&#xD;
&#xD;
         11. Lacking possibility of access via a dialysis catheter&#xD;
&#xD;
         12. Surgeries scheduled within 48 hrs of inclusion in the study&#xD;
&#xD;
         13. Advanced tumor disorder with life expectancy &lt; 1 month&#xD;
&#xD;
         14. Moribund patients, decision to forego therapy&#xD;
&#xD;
         15. Lacking consent&#xD;
&#xD;
         16. Participation in a different intervention study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nuernberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Erlangen-Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>90473</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>stefan john</investigator_full_name>
    <investigator_title>Prof. Dr. med. Stefan John</investigator_title>
  </responsible_party>
  <keyword>extracorporeal CO2 removal</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>Prismalung</keyword>
  <keyword>ARDS</keyword>
  <keyword>hypercapnia</keyword>
  <keyword>Changes in the arterial pCO2 value</keyword>
  <keyword>ventilated</keyword>
  <keyword>Hypercapnic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

